News

Clinical Trial News

June 2009: Week 24

• PSI completed enrollment in a phase II/III study of a novel biological agent in patients with metastatic renal cancer.
• PSI launched a phase III study of a novel biological agent in patients with relapsing-remitting multiple sclerosis.
• PSI launched a proof-of-concept study of a novel anticancer agent in patients with non-Hodgkin’s lymphoma.
• PSI completed the active treatment period in a phase II study of a novel antihyperglycemic in patients with type II diabetes.

June 2009: Week 23

• PSI launched a phase II study of a novel immunomodulator in patients with seasonal allergic rhinitis.
• PSI reached an interim enrollment milestone of 100 randomized patients in a phase II study of a novel antiaggregant in intermittent claudication.
• PSI reached an interim enrollment target of 650 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
• PSI completed the clinical phase of a phase III study of a novel cancer vaccine in patients with advanced renal cell carcinoma.

 May 2009: Week 22

• PSI reached an interim enrollment objective of 50 randomized patients in a phase III study of a novel antiviral in an adolescent population with chronic hepatitis B.
• PSI reached an interim enrollment target of 350 randomized patients in a phase III study of a novel insulin formulation in type I diabetes.
• PSI launched a phase III study of a novel antiviral in patients with chronic hepatitis C.
• PSI completed the active treatment period in a phase II study of a novel disease-modifying agent in patients with rheumatoid arthritis.

  May 2009: Week 21

• PSI launched a phase III study of a novel anticancer agent in patients with metastatic renal cancer.
• PSI launched a dose-escalation study of a novel biological agent in patients with inhibitor-complicated hemophilia.
• PSI initiated enrollment in a phase II dose-finding study of a novel prostaglandin modulator in patients with mild to moderate persistent asthma.
• PSI completed the active treatment period in a phase II study of a novel biological agent in patients with rheumatoid arthritis.

 May 2009: Week 20

• PSI reached an interim enrollment milestone of 50 randomized patients in a phase II study of a novel antiaggregant in intermittent claudication.
• PSI achieved an interim enrollment target of 50 randomized patients in a phase III study of a novel anticancer agent in metastatic breast cancer.
• PSI completed the active treatment period in a phase II study of a novel anticancer agent in patients with hormone-refractory prostate cancer.
• PSI completed the active treatment period in a phase II study of a novel anticancer agent in patients with metastatic NSCLC.

 May 2009:  Week 19

• PSI completed the active treatment period in a phase II study of a novel biological agent in patients with chronic lymphocytic leukemia.
• PSI reached an interim enrollment objective of 600 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
• PSI completed the active treatment period in a phase II study of a novel anticancer agent in patients with metastatic breast cancer.
• PSI completed the active treatment period in a phase III study of a novel anticancer agent in patients with non-Hodgkin’s lymphoma.

 April 2009: Week 18

• PSI launched a phase III study of a novel anticancer agent in patients with metastatic NSCLC.
• PSI completed enrollment in a phase II study of a novel biological agent in patients with receptor-positive advanced breast cancer.
• PSI completed a phase II study of a novel antibiotic in patients with complicated skin and skin structure infections.
• PSI completed a phase II study of a novel prostaglandin antagonist in patients with overactive bladder.

April 2009:  Week 17

• PSI completed a phase II study of a novel antiemetic in patients with chemotherapy-induced nausea and vomiting.
• PSI complete the active treatment period in a phase III study of a novel biological agent in patients with metastatic NSCLC.
• PSI reached an interim enrollment milestone of 550 randomized patients in a phase III study of a novel anticancer agent in metastatic NSCLC.
• PSI reached an interim enrollment target of 500 randomized patients in a phase II/III study of a novel biological agent in metastatic renal cancer.

April 2009:  Week 16

• PSI completed a phase III study of a novel antipsychotic in patients with schizophrenia.
• PSI reached an interim enrollment objective of 100 randomized patients in a phase II study of a novel biological agent in receptor-positive advanced breast cancer.
• PSI initiated enrollment in a phase III study of a novel biological agent in patients with inhibitor-complicated hemophilia.
• PSI completed a phase II study of a novel opioid antagonist in patients with alcohol dependence.

November 2008: PSI ACES FDA INSPECTIONS Download pdf

June 2008: PSI GAINS A FIRM FOOTHOLD IN LATIN AMERICA Download pdf